Summary: Findings revealed a profound therapeutic benefit: GLP-1 receptor agonists (such as semaglutide, tirzepatide, and liraglutide) do not merely drive physical weight reduction. Instead, they actively downregulate the core behavioral features of BED, significantly reducing active binge eating episodes, loss-of-control eating, and emotional eating patterns.
Key Facts
- Core Behavioral Suppression: The systematic review demonstrated that GLP-1 receptor agonists deliver therapeutic benefits extending far beyond basic metabolic weight loss. The medication profiles unmasked a significant, quantifiable drop in binge eating frequency, loss-of-control eating, and acute emotional eating episodes.
- The Cognitive Restraint Dilemma: While participants recorded an increase in cognitive or dietary restraint (intentionally monitoring and limiting food intake), the UCL team highlights this as a vital area requiring caution. It remains scientifically unclear whether this shift represents healthy, positive self-regulation or if it signals a potential vulnerability toward restrictive, pathological eating patterns like meal skipping.
- Central Reward Modification: Beyond simply delaying gastric emptying (slowing stomach processing), GLP-1 agonists operate directly within the central nervous system. The molecules cross into neurological networks to influence dopaminergic reward processing and impulse control centers, effectively dialing down the intense mental urges that drive compulsive eating behaviors.
- Lived Experience Integration: A primary structural strength of the UCL project was the direct integration of a lived experience panel. These advocates emphasized that long-term, sustainable recovery cannot rely on medication alone; instead, GLP-1 therapies must be woven into comprehensive care plans alongside psychological therapies, social support networks, and community efforts to eliminate weight bias.
- Critical Methodological Limitations: The authors note that the vast majority of existing trials carry a high risk of bias, were funded directly by pharmaceutical firms, and rarely enrolled participants holding a formal, standalone clinical diagnosis of BED. This highlights an urgent public health mandate for large, independently funded, long-term trials evaluating diagnosed populations.
- The Public Health Access Gap: Despite the expanding evidence pool, many individuals experiencing BED cannot access these medications through public healthcare systems, forcing patients to turn to private providers at substantial personal expense, a barrier the researchers hope this data will help dismantle.
Source: UCL
Drugs commonly used for weight loss, known as GLP-1 receptor agonists, have been found to reduce the key symptoms of binge eating disorder, in a new review of evidence led by University College London (UCL) researchers.
The systematic review and meta-analysis, published in eClinicalMedicine, found that weight loss drugs can reduce binge eating episodes, loss-of-control eating and emotional eating, and highlights its potential role to treat binge eating disorder as well as obesity.
Lead author Dr Ilaria Costantini (UCL Psychiatry) said: “Binge eating disorder, where people regularly eat an excessive amount of food while feeling they have lost control, is common and highly impairing, affecting over 17 million people worldwide.
“But treatment options are limited and there are currently no approved medications, so there remains a need for better ways to help people living with this condition. We found evidence that weight loss drugs may help to manage some key symptoms of binge eating disorder.”
In the largest study to date on the subject, the researchers pulled together evidence from 25 randomised controlled trials that took place in 12 countries on four continents, including data from 8,069 participants.
The studies were testing the effects of drugs targeting the appetite-regulating hormone GLP-1 such as semaglutide (often marketed under brand names Ozempic or Wegovy), tirzepatide (also known as Mounjaro) or liraglutide.
These drugs can suppress appetite by targeting the central nervous system and insulin secretion, and they can delay stomach emptying, while also potentially influencing brain processes of reward and impulse control.
The researchers found that the drugs yielded benefits beyond weight loss, including reducing binge eating, loss of control eating and emotional eating.
Participants also reported increased cognitive or dietary restraint (which relates to how much people intentionally limit their eating), but the researchers say more research is needed to understand this link.
The study’s first author, PhD candidate Izzy Emptage (UCL Psychiatry), said: “From the evidence available, we cannot say whether the increase in dietary restraint reflects a positive and helpful form of self-regulation or if it is a more dysfunctional pattern of eating. We hope that future research can clarify whether or not taking weight loss drugs might contribute to more pathological forms of eating restriction such as meal skipping.”
The researchers say their findings demonstrate that weight loss drugs could be an important part of treatment plans for people with binge eating disorder, alongside psychological therapies and social support.
Izzy Emptage added: “Many people with binge eating disorder cannot access weight loss drugs through their public healthcare providers, so many have to seek treatment privately at considerable personal cost.
“We hope that by highlighting the potential of weight loss drugs to help with binge eating symptoms, our findings will lead to further funding of larger high-quality studies in this area, to better understand how this medication could be used in practice and improve treatment options.”
Dr Costantini said: “One strength of our study is the involvement of a lived experience panel, who shared important insights into their views and concerns about the use of these medications for binge eating, as well as the challenges many people face in accessing treatment for binge eating disorder. Importantly, they emphasised that sustainable recovery is likely to depend not only on medication but also on psychological therapies and social support, as well as policy or community-level approaches to tackle societal norms and weight bias.”
The researchers note limitations of their study, as most of the trials included in the review had a high risk of bias and were funded by pharmaceutical companies, and they rarely included participants with a clinical diagnosis of binge eating disorder, which the researchers say limits the certainty of the findings.
They say that robust, independently-funded randomised controlled trials with long follow-up times that include people diagnosed with binge eating disorders are still needed to clarify the potential clinical role of these drugs to help treat binge eating disorder, and to determine whether the observed short-term benefits translate into meaningful and sustained improvements.
Funding: The study involved researchers in the UCL Faculties of Brain Sciences, Population Health Sciences and Medical Sciences alongside colleagues in the Universities of Exeter, Oxford, North Carolina and Karolinska Institute, and was supported by Wellcome, the Medical Research Foundation and the National Institute for Health Research (NIHR).
Key Questions Answered:
A: While GLP-1 agonists are famous for physical effects like slowing down digestion and shifting insulin secretion, their most profound impact on Binge Eating Disorder occurs directly inside the brain. These molecules travel into central nervous system pathways that govern reward processing, impulse control, and dopamine release. Compulsive binge eating is often driven by a hyperactive reward loop, where the brain demands massive quantities of food to achieve a sense of comfort or control. By quieting down this internal chemical urge and stabilizing reward signaling, GLP-1 drugs effectively dull the intense mental cravings and emotional impulses that trigger a binge episode in the first place.
A: Dietary restraint refers to the conscious, intentional effort an individual makes to limit and monitor how much food they eat. In the context of recovering from Binge Eating Disorder, a certain amount of structured restriction can be a positive sign of healthy self-regulation. However, first author Izzy Emptage warns that there is a fine line between helpful control and dangerous restriction. If a weight loss medication pushes dietary restraint too far, it could theoretically trigger a dysfunctional, pathological pattern of eating, such as severe calorie restriction or chronic meal skipping. Further long-term research is required to ensure these medications guide patients toward healthy balance rather than alternative forms of eating disorders.
A: A medical molecule can effectively quiet the brain’s reward centers and reduce physical appetite, but it cannot heal the underlying emotional, psychological, or situational triggers that caused the disorder to develop. Binge Eating Disorder is deeply intertwined with emotional distress, trauma, self-esteem challenges, and societal weight bias. The UCL lived experience panel strongly emphasized that sustainable, lifelong recovery requires a multi-layered approach. If a patient simply stops taking the medication without learning healthy cognitive coping mechanisms through psychological therapy and leaning on community support, the underlying emotional triggers will remain waiting to resurface.
Editorial Notes:
- This article was edited by a Neuroscience News editor.
- Journal paper reviewed in full.
- Additional context added by our staff.
About this psychopharmacology and eating disorder research news
Author: Chris Lane
Source: UCL
Contact: Chris Lane – UCL
Image: The image is credited to Neuroscience News
Original Research: Open access.
“The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis” by Tien-chen Lin (林天正), Charlotte H. Coles, Eissa Alfadil, Florian Fäßler, Andreas Husch, Sebastian Dupraz, Thorben Pietralla, Akihiro Narita, Max Schelski, Kevin C. Flynn, Sina Stern, Christoph Möhl, Brett J. Hilton, Franz Vauti, Hans-Henning Arnold, Florian K. M. Schur & Frank Bradke. EClinicalMedicine
DOI:10.1016/j.eclinm.2026.104007
Abstract
The effectiveness of glucagon-like peptide-1 receptor agonists (GLP-1RAs) on binge eating in patients with obesity: a systematic review and meta-analysis
Background
Glucagon-like peptide-1 receptor agonists (GLP-1RAs), widely used for weight management and type 2 diabetes, may reduce binge eating behaviours and body dissatisfaction, but there are concerns that they might increase eating restraint. We evaluated the effectiveness of GLP-1RAs for binge eating severity and related eating behaviours.
Methods
We conducted a systematic review and meta-analysis of randomised controlled trials (RCTs) comparing any GLP-1RA with placebo or active comparators reporting validated measures of binge eating, disinhibited eating, and loss of control eating. We searched MEDLINE, Embase, PsycINFO, and the Cochrane Central Register of Controlled Trials for RCTs published from Jan 2005 to April 2026. Trials including participants with severe physical comorbidities (e.g., cancer) were excluded. Standardised mean differences (Hedges’ g) based on change-from-baseline scores or post-intervention raw mean differences (MD) with 95% CIs were estimated using random-effects models, with heterogeneity quantified using I2 and τ2; publication bias was not formally assessed due to the limited number of studies. Intervention effects on body image concerns were not meta-analysed due to limited data. PROSPERO: CRD42024570728.
Findings
Twenty five RCTs (n = 8069; ∼two-thirds female; majority White) met inclusion criteria. Compared with control conditions, participants allocated to GLP-1RAs reported moderate reductions in binge eating (n = 2106; k = 9; g = −0.23 [95% CI −0.36 to −0.10]), loss of control eating (n = 362; k = 5; MD = −18.38 [–23.34 to −13.43]) and eating disinhibition (n = 911; k = 13; g = −0.54 [−0.90 to −0.18]); alongside lower emotional eating (n = 429; k = 4; g = −0.30 [−0.51 to −0.09]) and higher cognitive or dietary restraint (n = 911; k = 13; g = 0.31 [0.17–0.44]). Effects were larger in trials enrolling participants with binge eating disorder. All studies were rated as having high risk or some concerns of bias, and heterogeneity was substantial.
Interpretation
GLP-1RAs reduced binge eating-related behaviours and emotional eating and increased cognitive or dietary restraint, though whether restraint is pathological is unclear. Given heterogeneity and high risk of bias, adequately powered trials targeting individuals with diagnosed binge eating disorder and longer follow-up are needed to inform clinical practice.
Funding
Wellcome Trust and Medical Research Foundation.
